PharmaDrug Inc. Completes Debt Restructuring
PharmaDrug Inc. Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announced debt restructuring (see press release dated November 7, 2023).
安大略省多倫多--（Newsfile Corp.，2023 年 11 月 15 日）-PharmaDrug Inc.（CSE：PHRX）（OTC Pink：LMLLD）（”PharmaDr“或者”公司“），很高興地宣佈，它已經完成了先前宣佈的債務重組（見2023年11月7日的新聞稿）。
Under the restructuring, the Company agreed with the holders of its unsecured convertible debentures that matured without payment earlier this year to exchange the outstanding $1,219,768 of indebtedness for new unsecured convertible debentures with an aggregate principal amount of $1,280,756. The debentures mature one year from the date of issuance. The Company has the option to extend the maturity date up to two times for one year extensions each time. If such option to extend is exercised then at the extension time the principal of the debenture will be increased to reflect both any accrued and unpaid interest as well as a 5% renewal fee. The debentures will bear interest at a rate of 12% per annum payable quarterly. If the interest is not paid when due then interest will be charged on such outstanding interest at a rate of 15% per annum. The debentures may be converted into units ("Units") at a price of $0.05 per Unit with each Unit being comprised of one common share in the capital of the Company and one common share purchase warrant with each such warrant entitling the holder to acquire one common share in the capital of the Company at a price of $0.05 per share at any time on or before the three year anniversary of the issuance of the debentures. The conversion feature will not be exercisable by the holder if it would take their holdings of the Company above 10% of the outstanding common shares of the Company. The debentures and underlying securities will be subject to a hold period that will expire on March 15, 2023.
在重組中，公司與今年早些時候無償到期的無抵押可轉換債券的持有人達成協議，將未償還的1,219,768美元債務兌換成本金總額爲1,280,756美元的新無抵押可轉換債券。債券自發行之日起一年後到期。公司可以選擇將到期日延長至兩次，每次延長一年。如果行使這種延期權，則在延期時，債券的本金將增加，以反映任何應計和未付利息以及5％的續期費。債券將按每年12％的利率支付利息，按季度支付。如果未在到期時支付利息，則將按每年15％的利率對此類未償利息收取利息。債券可以轉換爲單位（”單位“）價格爲每單位0.05美元，每個單位由公司資本中的一股普通股和一張普通股購買權證組成，每份此類認股權證使持有人有權在債券發行三週年之日或之前的任何時候以每股0.05美元的價格收購公司資本中的一股普通股。如果持有人持有的公司股份超過公司已發行普通股的10％，則持有人將無法行使轉換功能。債券和標的證券的持有期將於2023年3月15日到期。
In addition the Company has agreed to settle $227,658.03 of indebtedness with certain service providers through the issuance of an aggregate of 4,553,160 common shares at a deemed issue price of $0.05. The common shares will be subject to a hold period that will expire on March 15, 2023.
此外，公司已同意通過發行總額爲4,553,160股普通股來償還某些服務提供商的227,658.03美元的債務，視同發行價格爲0.05美元。普通股的持有期將於2023年3月15日到期。
Finally, the Company confirms that it will not be issuing the additional common share purchase warrants to the holders of the company's secured convertible debentures as referenced in the November 7, 2023 press release.
最後，公司確認不會向2023年11月7日新聞稿中提及的公司有擔保可轉換債券的持有人發行額外的普通股購買權證。
About PharmaDrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. PharmaDrug also owns 100% of SecureDose Synthetics Inc. ("SecureDose"), a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.
關於 PharmaDrug Inc.
PharmaDrug是一家專業製藥公司，專注於受控物質和天然藥物（例如迷幻藥和先前批准的藥物）的研究、開發和商業化。PharmaDrug擁有Sairiyo Therapeutics（“Sairiyo”）51％的股份，Sairiyo Therapeutics（“Sairiyo”）是一家專門研究和重建成熟天然藥物的生物技術公司，其目標是在美國和歐洲通過臨床試驗和相關的監管批准程序。Sairiyo目前正在開發頭孢黃鹼的專利重組配方，該藥物已顯示出相當大的經第三方驗證的治療傳染病和罕見癌症的潛力。Sairiyo還在迷幻藥領域進行研發，用於治療非神經精神疾病。PharmaDrug還擁有SecureDose Synthetics Inc.（“SecureDose”）的100％股份，該公司是一家藥物研發公司，專注於開發當前現有藥物的合成配方，以進行潛在的商業化和分銷。
For further information, please contact:
欲了解更多信息，請聯繫：
Robert J. Steen, Chairman and CEO
robsteen57@gmail.com
(416) 400-7086
羅伯特·斯蒂恩，董事長兼首席執行官
robsteen57@gmail.com
(416) 400-7086
Caution Regarding Forward-Looking Information:
關於前瞻性信息的注意事項：
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所尚未審查本新聞稿的充分性或準確性，也不承擔任何責任。
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward looking statements in this press release relate to the development of the Company's business. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.
本新聞稿可能包含基於當前預期的前瞻性陳述和信息。這些聲明不應被視爲對公司未來業績或業績的保證。本新聞稿中的前瞻性聲明與公司業務發展有關。此類陳述涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際結果、業績或成就與此類陳述所暗示的結果存在重大差異。
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals..
前瞻性信息受已知和未知的風險、不確定性和其他因素的影響，這些因素可能導致公司的實際業績、活動水平、業績或成就與此類前瞻性信息所表達或暗示的結果存在重大差異。此類風險和其他因素可能包括但不限於：一般業務、經濟、競爭、政治和社會的不確定性；一般資本市場狀況和證券市場價格；公司未來經營的實際業績；競爭；影響公司的立法變化；獲得和維持所需許可證和批准的能力、以可接受的條件獲得外部融資的時間和可用性；缺乏合格的熟練勞動力或關鍵人物的流失。
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
可能導致實際業績與前瞻性信息存在重大差異的其他風險因素的描述可在SEDAR+網站上公司的披露文件中找到，網址爲。儘管公司試圖確定可能導致實際業績與前瞻性信息中包含的結果存在重大差異的重要因素，但可能還有其他因素導致業績與預期、估計或預期的結果不符。因此，讀者不應過分依賴前瞻性信息。提醒讀者，上述因素清單並不詳盡。進一步提醒讀者不要過分依賴前瞻性信息，因爲無法保證前瞻性信息所依據的計劃、意圖或期望會實現。儘管管理層在編制時認爲此類信息是合理的，但可能被證明是不正確的，實際結果可能與預期結果存在重大差異。
The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
公司的證券未根據經修訂的1933年《美國證券法》（“美國證券法”）或適用的州證券法進行註冊，未經註冊或未獲得此類註冊要求的適用豁免，不得向美國個人或 “美國個人”（該術語的定義見《美國證券法案》）或適用的州證券法進行發行或出售，或爲其賬戶或利益。本新聞稿不構成出售要約或徵求買入要約，也不得在美國或任何將此類要約、招攬或出售爲非法的司法管轄區出售證券。
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
本警示聲明明確限制了本新聞稿中包含的前瞻性信息。本新聞稿中包含的前瞻性信息代表了公司截至本新聞稿發佈之日的預期，因此，在該日期之後可能會發生變化。但是，除非適用的證券法明確要求，否則公司明確否認任何更新或修改任何前瞻性信息的意圖或義務，無論是由於新信息、未來事件還是其他原因。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。